Latest Thyroid News
MONDAY, Jan. 26, 2015 (HealthDay News) -- Natpara (parathyroid hormone) has been approved by the U.S. Food and Drug Administration to control low blood calcium among people with hypoparathyroidism.
Hypoparathyroidism is a rare disease that occurs when the body doesn't secrete enough parathyroid hormone, which regulates blood levels of calcium and phosphorus.
Hypoparathyroidism is typically caused by malfunctioning or surgically removed parathyroid glands. The condition affects about 60,000 people in the United States, the FDA said in a news release. Symptoms commonly include numbness, tingling, muscle twitching, cramps, abnormal heart rhythm and seizures. Longer-term complications may include kidney damage, kidney stones and cataracts.
Natpara, a once-daily injection, was evaluated in a clinical study of 124 people. Forty-two percent of those treated with Natpara achieved normal blood calcium levels, the FDA said.
Natpara is produced by NPS Pharmaceuticals, based in Bedminster, N.J.
-- Scott Roberts
Copyright © 2015 HealthDay. All rights reserved.
Health Solutions From Our Sponsors